Table 2.
PAM50 subtype | Age, y |
Race |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
≥50 | <50 | OR* (95% CI) | OR† (95% CI) | P‡ | White, | Black, | OR§ (95% CI) | OR† (95% CI) | P‡ | |
No. (%) | No. (%) | No. (%) | No. (%) | |||||||
LumA | 217 (44.6) | 160 (35.8) | 1.00 (reference) | 1.00 (reference) | .06 | 228 (50.2) | 149 (31.0) | 1.00 (reference) | 1.00 (reference) | <.001 |
Basal-like | 120 (24.6) | 129 (28.7) | 1.54 (1.10 to 2.14) | 1.08 (0.72 to 1.62) | 80 (17.6) | 169 (35.2) | 3.11 (2.22 to 4.37) | 1.93 (1.27 to 2.93) | ||
LumB | 94 (19.3) | 100 (22.4) | 1.47 (1.04 to 2.09) | 1.21 (0.83 to 1.77) | 98 (21.6) | 96 (20.0) | 1.45 (1.02 to 2.06) | 1.14 (0.78 to 1.68) | ||
HER2-enriched | 56 (11.5) | 58 (13.0) | 1.45 (0.95 to 2.22) | 1.12 (0.70 to 1.79) | 48 (10.6) | 66 (13.8) | 2.04 (1.33 to 3.13) | 1.43 (0.88 to 2.30) | ||
Normal-like | 25 | 21 | – | – | 26 | 20 | – | – |
Adjusted for race. CI = confidence interval; HER2 = human epidermal growth factor receptor 2; OR = odds ratio.
Additionally adjusted for tumor size (≤2 cm vs > 2 cm), nodal status (negative vs positive), stage (I and II vs III and IV), and grade (I and II vs III).
Two-sided chi-square P values exclude 46 cases with normal-like PAM50 subtype and 138 cases with unclassified/missing clinical subtype.
Adjusted for age.